DeCure for Linear skin defects with multiple congenital anomalies 3
DeCure's autonomous Dermatology AI scientist is researching a drug-repurposing hypothesis for linear skin defects with multiple congenital anomalies 3 — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleLinear skin defects with multiple congenital anomalies 3 maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for linear skin defects with multiple congenital anomalies 3 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
The abstracts provided do not describe any drug treatment or clinical trial for linear skin defects with multiple congenital anomalies 3. One 2014 report on CLOVES syndrome, a different overgrowth disorder caused by mosaic PIK3CA mutations, notes that the infant died at 29 days of life despite prenatal detection of the mutation; no drug intervention is mentioned. The remaining abstracts discuss aplasia cutis congenita and other congenital skin defects as rare, heterogeneous conditions with no single cause, and describe surgical closure of a myelomeningocele using skin from a stillborn twin. No pharmacological therapy appears in any of these texts.
No drug is named, no response rate or survival benefit is reported, and no molecular target for treatment is proposed in these abstracts. The 2014 paper explicitly states that molecular confirmation of mosaic mutations is difficult and may require multiple approaches, but does not link any drug to the pathway involved.
What is missing is any clinical trial, any drug repurposing hypothesis, any patient stratification strategy, and any funding for research into this specific disease. The abstracts do not even establish a consistent genetic or mechanistic basis for linear skin defects with multiple congenital anomalies 3 that could guide a drug-repurposing effort.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Archives of Dermatology · 1962 · 50 citations
Aplasia Cutis Congenita
AbstractCongenital defect of the skin constitutes one of the rare and interesting anomalies peculiar to the newborn. Its extreme rarity, in comparison with the great frequency of minor aberrations such as disturbances of pigment, hair, glandular development, and vascular supply, can only mean that the natural, inherent factors at work in covering the body with some kind of an epithelial layer are far more ancient, fundamental, deepseated, tenacious, and stubborn than those influences which prescribe the finer details of that covering once it is established. Frank defects, absence of the skin, must invoke far more powerful, more incisive, genetic influences or have as etiology active trauma, physical violence, or other external forms of tissue destruction.<sup>1</sup> A variety of physical and endogenous factors may lead to arrested development of the embryonic skin.<sup>2</sup>There are many theories as to the cause, and no single one can explain all cases.<sup>3</sup>
The Medical Journal of Australia · 1972 · 10 citations
CONGENITAL SCALP DEFECTS IN BROTHER AND SISTER
AbstractCongenital scalp defects are uncommon skin defects which usually occur alone, but are sometimes associated with other congenital cutaneous defects, or congenital abnormalities. They are usually small and uncomplicated. A larger variety is more commonly associated with underlying defects of the skull, and is more liable to complications. They occasionally occur in relatives. This rare, familial defect is described in siblings.
Clinical Case Reports · 2021 · 4 citations · open access
Isolated aplasia cutis congenita: A report of two cases
AbstractCongenital skin dysplasia, especially isolated scalp defects, is difficult to detect prenatally. The prognosis for isolated congenital scalp defects is good. Treatment options include conservative treatment and surgery. The choice of treatment depends on the patient's individual circumstances.
Closure of Myelomeningocele Using Skin from Stillborn Twin
AbstractWe report a case of homologous skin transplantation from a stillborn twin to the surviving twin for coverage of a myelomeningocele defect. Genetic studies were not available preoperatively, however, similar morphogenetic anomalies of the twins suggested monozygosity. Long-term follow-up revealed a well-healed graft. Cutaneous genetics and literature review of twin homologous skin transplantation are presented.
Focal skin defect, limb anomalies and microphthalmia
AbstractWe describe two unrelated female patients with congenital single focal skin defects, unilateral microphthalmia and limb anomalies. Growth and psychomotor development were normal and no brain malformation was detected. Although eye and limb anomalies are commonly associated, clinical anophthalmia and limb defects have not been reported with single focal aplasia of the skin. The described features may be compatible with a mild phenotypic variant of Goltz syndrome or may represent a previously undescribed syndrome.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
